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Abstract
Background: The human epidermal growth factor receptor 2 (HER2) and p53 pathways may be involved in
chemotherapy sensitivity and/or resistance. We explore the value of HER2 and p53 status to foretell docetaxel
sensitivity in advanced breast cancer.
Methods: HER2 and p53 expression was analysed in 36 (median age 55 yrs; range 37-87) metastatic breast cancer
patients receiving docetaxel-based first-line chemotherapy. HER2 was determined by immunohistochemistry (IHC)
and fluorescence in situ hybridization (FISH), p53 was tested by IHC. We correlate the expression of study
parameters with pathologic parameters, RECIST response and survival. The standard cut-off value of 2 was used to
determine HER2 overexpression while p53 mean expression level was used to divide low/high expressors tumors.
Results: Median time to progression and overall survival were 9 (range 2 - 54) and 20 (range 3 - 101) months.
Overall response rate was 41.6%. Nine cases showed HER2 overexpression. HER2 was more frequently
overexpressed in less differentiated (p = 0.05) and higher stage (p = 0.003) disease. Mean FISH-HER2 values were
significantly higher in responder than in non-responder pts (8.53 ± 10.21 vs 2.50 ± 4.12, p = 0.027). Moreover, HER2
overexpression correlates with treatment response at cross-tabulation analysis (p = 0.046). p53 expression was only
associated with higher stage disease (p = 0.02) but lack of any significant association with HER status or docetaxel
response. No significant relation with survival was observed for any parameter.
Conclusion: Our data seem to indicate that FISH-determined HER2 status but not p53 is associated with docetaxel
sensitivity in metastatic breast cancer.
Background
Breast cancer (BC) is the leading cause of cancer and
the second leading cause of cancer death in women in
the USA [1] and its incidence is increasing in many
countries, including Italy [2] thus representing a major
health problem. To date, the role of chemotherapy in
BC treatment is certain and taxanes are widely used in
both early and advanced setting [3,4] but we have no
validated sensitivity and/or resistance predictive factor
and, hence, the search for a taxane-specific predictive
marker is an hot topic. Colled as the “guardian of the
genome” [5] and the “cellular gatekeeper” [6], the p53
protein acts as cell modulator by driving lots of stress-
inducing signals to different antiproliferative cellular
responses [7]. p53 can be activated in response to DNA
damage (such as cytotoxic agents), oncogene activation
or hypoxia resulting to cellular outputs such as apopto-
sis, cell-cycle arrest, senescence, or modulation of autop-
hagy [8-10]. Although about 50% of BCs harbours TP53
gene mutations [11,12], the biological role and clinical
importance of p53 alterations in BC are still unclear.
This maybe related to the very complicated and exten-
sive p53 network and to technical problems associated
with surrogate markers to identify TP53 gene defects, as
most detection tests lack sensitivity and specificity.
Despite its limits, immunohistochemical p53 detection
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demonstrated in numerous studies to be a prognostic
factor in BC [11-17] and that it may determine the sen-
sitivity to specific therapeutic agents [18-22]. Some evi-
dences may indicate that abnormal p53 expression
could be associated with taxane sensitivity but its speci-
fic predictive role is unclear [22-24].
Another leading cell growth regulator in BC is the
human epidermal growth factor receptor (HER) 2
(HER2; erbB2/neu). The HER2 oncogene encodes one of
four trans-membrane receptors within the erbB family.
Its over-expression, which occurs in approximately 25%
of all breast cancer tumors, is associated with a shor-
tened disease-free interval and poor survival [25]. HER2
blockage in preclinical models of human BC and in pri-
mary breast tumors from women treated with HER2-
targeted therapies leads to the inhibition of survival
pathways, which in turn induces tumor cell apoptosis
[26]. The clinical benefit of HER2 inhibition by its speci-
fic monoclonal antibody trastuzumab is meaningful in
both early and advanced disease [27,28]. HER2 status
may also influence chemotherapy sensitivity as proposed
by Gennari et al [29] that focused on the adjuvant set-
ting showing that the added benefits of adjuvant che-
motherapy with anthracyclines seems to be reserved to
breast cancer harboring HER2 overexpression or
amplification.
On this grounds, we analysed the relationship between
HER2 and p53 expression and response to first-line doc-
etaxel based chemotherapy in advanced BC finding that
FISH-determined HER2 status but not p53 could predict
docetaxel sensitivity.
Methods
Patient characteristics and tissue samples
Tumor samples were obtained from breast cancer
patients who underwent surgery at Versilia Hospital in
Lido di Camaiore (Italy) from 2000 to 2004. A total of
36 breast cancer patients (median age 55 yrs; range 37-
87) receiving between 2001 and 2005 a docetaxel-based
first-line chemotherapeutic regimen for metastatic dis-
ease were retrospectively selected for the study. Study
population characteristics are shown in table 1. Mean
time from initial diagnosis to first relapse was 15.8 ±
6.5 months. Location of metastatic deposits includes
bone (21/36), liver (21/36), lung (16/36), lymphnodes
(14/36) and local recurrence (3/36) with 27 out of 36
patients presenting with multiple disease sites; remain-
ing 9 patients with single-site metastasis presented with
measurable non-bone disease. Patients receiving pre-
operative chemotherapy, having a family history of
breast cancer or receiving docetaxel as part of adjuvant
treatment were excluded as well as those for whom fol-
low-up data were missing. Adjuvant treatment was per-
formed in all patients but two as follow: 18 patients
received an association of 5-fluorouracil (5-FU), epiru-
bucin and cyclophosphamides (FEC) for 6 cycles, 11
patients received an association of epirubucin and cyc-
lophosphamides (EC) for 4 cycles, and remaining
5 patients received an association of cyclophosphamides,
methotrexate and 5-FU (CMF) for 6 cycles.
Table 1 Study population characteristics (n = 36)
Median [range] age (yr) 55 [37-87]
Histotype#
Invasive ductal carcinoma 28 (77.7%)
Invasive lobular carcinoma 5 (13.8%)
Mixed (ductal and lobular) 2 (5.5%)
Undifferentiated 1 (3.0%)
Grading°
G2 21 (58.3%)
G3 15 (41.7%)
ER status
Negative 14 (38.8%)
Positive 22 (61.2%)
PgR status
Negative 13 (36.1%)
Positive 23 (63.9%)
HER2 status*
Negative 27 (75.0%)
Positive 9 (25.0%)
Adjuvant chemotherapy^
FEC 18 (52.9%)
EC 11 (32.4%)
CMF 5 (14.7%)
Mean ± SD time to first relapse (months) 15.8 ± 6.5
Metastatis sites
Bone 21 (58.3%)
Liver 21 (58.3%)
Lung 16 (44.4%)
Lymphnodes 14 (38.8%)
Local 3 (8.3%)
Chemotherapy”
TXT75 14 (38.8%)
TXT25 8 (22.2%)
TXT75+C 5 (13.8%)
TXT75+T 9 (25.2%)
Treatment best response
Complete response 1 (2.7%)
Partial response 14 (38.8%)
Stable disease 12 (33.3%)
Disease progression 9 (25.2%)
Time to disease progression (months)
Median [range] 9 [2-54]
Overall survival (months)
Median [range] 20 [3-101]
#According to WHO hystological typing of breast tumor (Ref. 32). °According
to Elston and Ellis classification (Ref. 31). *Pre-study determination. “See text
for regimen details. ^on 34 pts.
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All patients received docetaxel-based first-line che-
motherapy for metastatic disease. In particular, 14 out
of 36 patients received six cycles docetaxel (75 mg/m2)
every 3 weeks (TXT75), 8 patients received docetaxel
(25 mg/m2) on a weekly basis (TXT25), 5 patients
received a combination of docetaxel (75 mg/m2) on day
1 plus capecitabine (1000 mg/m2 bid day 1-14) every
3 weeks (TXT75+C) and the remaining 9 patients with
HER2-positive disease received a combination of doce-
taxel (75 mg/m2) and trastuzumab (8 mg/kg loading
dose then 6 mg/kg) both on day 1 every 3 weeks
(TXT75+T) (Table 1). Every treatment was planned for
up to 6-9 months. Causes for early treatment stop were
unacceptable toxicity, disease progression or patient
refusal. Trastuzumab was administered alone after doce-
taxel discontinuance as maintenance therapy until dis-
ease progression in 6 responder patients. Tumor
assessment was performed every 3 months by CT-scan
and/or chest X-ray coupled with abdomen ultrasound
depending on those used at baseline. Time to progres-
sion (TTP) was calculated from the date of treatment
start to the date of first-documented progression. Over-
all survival (OS) was defined as the time interval
between the start of treatment and death or last follow-
up contact. Treatment response was assessed according
to RECIST criteria and we consider as responder a
patient achieving a complete (CR) or partial (PR)
response to treatment. Patients achieving disease stabili-
zation (SD) or disease progression (PD) were considered
as not-responders. Anyway, we planned a secondary
analysis considering as responders even patients achiev-
ing disease stabilization as best result. Median TTP was
9 (range 2 - 54) months and overall response rate
(ORR) was 41.6% (14 out of 36) with 11 and 8 pts
experiencing disease stabilization and progression
respectively. Median OS was 20 (range 3 - 101) months.
Being a retrospective analysis patients were not asked to
sign any informed consent; anyway samples were coded
and the names of the patients were not revealed. All
available clinico-pathological data were collected and
stored in an appropriate database. Age, tumor grade and
stage [30,31], size, histotype,(32) estrogen receptor (ER)
and progesterone receptor (PgR) status were considered.
Immunoistochemistry
P53 expression was evaluated by immunohistochemistry
(IHC) while HER2 expression was evaluated both by
IHC and fluorescence in situ hybridization (FISH - see
next paragraph). All IHC analyses were performed on
routinely processed, formalin-fixed and paraffin-
embedded tissue samples obtained from primary tumor.
For p53 IHC analysis, representative tumor sections
(3 μm) were deparaffinized, rehydrated and immunos-
tained using antigen retrieval by microwave technique.
After endogenous peroxidase blocking sections were
incubated for 45 min at 37°C with a 1:50 dilution of pri-
mary mouse anti-human p53 monoclonal antibody
(clone: DO-7, isotype IgG2b) (Dako), then immunos-
tained with secondary antibodies and finally counter-
stained with hematoxylin. Sections of known positive
mammary carcinoma were used as positive controls.
Negative controls were obtained by omitting the primary
antibodies. For p53 only a clear nuclear staining in the
absence of cytoplasmic background coloration was con-
sidered positive. A minimum of 1.000 cells were
counted for each tumor and immunoreactivity was
expressed as a percentage of positive cells on the total
number of tumor cells. A value of 11% of positive cells,
corresponding to the mean value of p53 expressing
tumor cells, was used as cut-off to distinguish high and
low expressing tumors.
HER2 IHC evaluation was realized by the streptavidin-
biotin-peroxidase complex technique (StreptABC,
DAKO) as standard for the time of analysis. Tissue sec-
tions were deparaffinized and underwent antigenic
retrieval and endogenous peroxidase blocking. Sections
were first incubated with polyclonal primary antibodies
against c-erbB-2 (A0485, DAKO) with a 1:500 dilution,
then incubated in secondary biotinylated antibody and
finally counterstained with Hematoxylin. Immunohisto-
chemical analyses of c-erbB-2 expression describe the
intensity and staining pattern of tumor cells. The FDA-
recognized test, the Herceptest™ (DAKO), describes
four categories: no staining, or weak staining in fewer
than 10% of the tumor cells (0); weak staining in part of
the membrane in more than 10% of the tumor cells
(1+); complete staining of the membrane with weak or
moderate intensity in more than 10% of the neoplastic
cells (2+); and strong staining in more than 10% (3+).
Cases with 0 or 1+ score were regarded as negative; the
ones with 3+ score were regarded as positive while 2+
cases underwent FISH and categorized accordingly. All
immunostained specimens were evaluated by two obser-
vers independently (PV and AC) without knowledge of
clinical characteristics and/or follow-up information and
the discrepant cases were jointly re-evaluated and agree-
ment was met.
Dual-color Fluorescence in situ Hybridization
HER2 amplification was analyzed on microdissected
tumor samples using FISH HER2 PharmDx (Dako,
K5331), which contains both fluorescently-labeled
HER2/neu gene and chromosome 17 centromere probes.
Microdissection was performed by an expert pathologist
different from ones that performed IHC evaluation.
In brief, sections were deparaffinized, heat-pretreated in
citrate buffer at 80°C for near 1 hour, digested with
pepsin at room temperature for few minutes and
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dehydrated in graded ethanol. After the HER2/CEN17
probe mix was applied to the dry slides. The slides
were then incubated in hybridizer (Hybridizer Instru-
ment for in situ hybridization, DAKO, S2450) for
denaturation at 82°C for 5 minutes and hybridization
at 45°C for about 18 hours. The slides were re-
dehydrated in graded ethanol. FISH analyses were per-
formed according to the HER2 FISH PharmDx (Dako)
criteria. In each case, 100 non-overlapped, intact inter-
phase tumor nuclei identified by DAPI staining were
evaluated, and gene (red signal) and CEN17 (green sig-
nal) copy numbers in each nucleus were assessed. The
cases were considered to be amplified when the aver-
age copy number ratio, HER2/CEN17, was ≥ 2.0 in all
nuclei evaluated or when the HER2 signals formed a
tight gene cluster. Among the cases in which the gene
was not amplified, samples showing more than four
copies of the HER2 gene and more than four CEN17
in more than 10% of the tumor cells were considered
to be polysomic for chromosome 17.
Statistical analysis
Correlation between p53, HER2 and other molecular
and clinical parameters were assessed by contingency
table methods and tested for significance using the Pear-
son’s chi-square test. Mean values were compared using
the student-T test. Survival curves were calculated using
the Kaplan-Meier method and tested for significance
using the log-rank test. Univariate and multivariate rela-
tive risks were calculated using Cox proportional
hazards regression. Statistical analyses were performed
using NCSS software. All tests were two-tailed, and p <
0.05 was considered to be significant.
Results
Expression levels of p53 ranged from 0% to 70% of immu-
nostained nuclei with a mean expression value of 11%
(median = 5%) (Figure 1 and 2). Using this mean value as
cut-off to distinguish high and low expressing tumors,
staining was considered high in 11 (30.5%) out of 36
tumors in our series (similar results were obtained using
as cut-off the median value). P53 expression levels were
only related to disease stage with higher p53 levels in
higher stage disease (p = 0.02) but lack of any significant
association with HER2 status, other clinic-pathologic para-
meters (age, ER and PgR status, Ki67 and tumor grading)
or docetaxel response (Table 2). Even comparing mean
p53 expression levels between responders vs not-respon-
ders patients we did not find any significant difference
(not shown) and mean TTP (8.6 ± 7.0 vs 9.2 ± 11.9
months; p = ns) and OS (21.6 ± 13.0 vs 19.8 ± 10.2
months; p = ns) did not differ between low and high p53
groups. Morever, no significant relation with survival para-
meters was observed for p53 at Kaplan-Meier analysis.
Conversely, HER2 positive breast tumors appear to be,
as expected, less differentiated and of higher stage more
frequently than negative ones (Table 3). In accordance
with literature data, 6 out of 9 (66.6%) HER2 positive
while only 9 out 27 (33.3%) HER2 negative patients
respectively responded to docetaxel treatment and this
difference was significant (Table 3). Confirmatory results
were obtained by student-T test on mean FISH values
between responders vs not-responders patients. In fact,
responder group showed significantly higher mean FISH
values than not-responder (8.53 ± 10.21 vs 2.50 ± 4.12,
p = 0.027). All HER2-positive patients received trastuzu-
mab in combination with docetaxel while HER2-negative
Figure 1 Immunohistochemical positive staining of p53 in a
representative case of high-grade (G3) ductal carcinoma.
Immunostaining shows a clear and wide nuclear staining in an high
grade (G3) invasive ductal carcinoma. Original magnifications: ×100
(inset ×250).
Figure 2 p53 immunohistochemical negative staining in a
grade 2 ductal carcinoma. The wide majority of nuclei showed no
staining with the exception of one clear positive nucleus (arrow) in
the upper left corner. Original magnifications: ×100 (inset ×250).
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ones were treated with docetaxel with a known influence
on and response rate and outcome. To shrink the possi-
ble treatment-related bias we test the FISH value differ-
ence between docetaxel responders and not-responder in
HER2-negative subgroup (n = 27) so removing trastuzu-
mab treatment-related bias. Taking into account the
smaller sample size and the lower FISH values (< 2), we
found a non-statistically significant difference in mean
FISH value with responders patients having higher values
(1.64 ± 0.157 vs 1.38 ± 0.146; p = ns). We also performed
the same analysis in FISH-positive group (11 pts all
receiving docetaxel plus trastuzumab) and we observed
also in this small subgroup a similar behaviour (16.86 ±
9.78 vs 9.85 ± 10.53; responders vs not-responders; p =
0.18 ns).
Mean TTP (positive vs negative: 7.9 ± 8.1 vs 9.8 ± 9.4
months; p = 0.18 ns) and OS (positive vs negative:
18.1 ± 11.7 vs 21.2 ± 12.1 months; p = 0.12 ns) showed
a only modest trend towards significance with HER2
positive patients having worse prognosis. Kaplan-Meier
survival analysis did not show a significant separation
between HER2 positive and negative groups (Figure 3
for OS curves). The same results for both study mole-
cules were obtained even incorporating in responders
group patients achieving SD (not shown). Neither HER2
expression nor p53 status were independent predictors
of OS and TTS at Cox regression analysis.
Lastly, we also observed at cross-tabulation analysis a
clear correlation between HER2 testing with IHC and
FISH (p = 0.001). Mean ± SD FISH values in negative
and positive groups were 1.51 ± 0.223 and 13.09 ± 9.98
respectively.
Discussion
Some preliminary comments about study limitations will
facilitate the discussion of the results. First, presented
data originate from a retrospective analysis that is natu-
rally exposed to selection bias. Second, the relative small
sample size could reduce the strength of statistical asso-
ciations and dramatically affects survival analyses. Third,
all patients did not receive the same chemotherapy regi-
men both in term of schedule (weekly or every 3 weeks
administrations) and in term of associated drug (5 patient
Table 2 p53 expression in relation to main tumor
characteristics and treatment response
p53 expression
Total Low High p value
Age
< 55 yrs 18 13 5 n.s.
≥55 yrs 18 12 6
ER expression
Negative 14 8 6 n.s.
Positive 22 17 5
PgR expression
Negative 13 9 4 n.s.
Positive 23 16 7
Grading#
G2 21 17 4 n.s.
G3 15 8 7
Stage*°
I-IIA 17 15 2 0.02
IIB-III 16 7 9
HER2
Negative” 27 21 6 n.s.
Positive” 9 4 5
Ki67
Negative 22 15 7 n.s.
Positive 14 10 4
Treatment response
CR+PR 15 11 4 n.s.
SD+PD 21 14 7
n.s. = not significant; CR = complete response; PR = partial response; SD =
stable disease; PD = disease progression. #According to Elston and Ellis
classification (Ref. 31). *According to UICC-TNM classification of malignant
tumours, sixth edition 2002 (Ref. 30). °At initial diagnosis time. “IHC 0,1+ and
2+ FISH negative were regarded as negative while IHC 3+ or 2+ FISH positive
were regarded as positive.
Table 3 HER2 expression in relation to main tumor
cheracteristics and treatment response
HER2 expression”
Total Low High p value
Age
< 55 yrs 18 13 5 n.s.
≥55 yrs 18 14 4
ER expression
Negative 14 10 4 n.s.
Positive 22 17 5
PgR expression
Negative 13 9 4 n.s.
Positive 23 18 5
Grading#
G2 21 18 3 0.05
G3 15 8 7
Stage*°
I-IIA 17 16 1 0.003
IIB-III 16 8 8
Ki67
Negative 22 18 4 n.s.
Positive 14 9 5
Treatment response
CR+PR 15 9 6 0.046
SD+PD 21 18 3
“IHC 0, 1+ and 2+ FISH negative were regarded as negative while IHC 3+ or
2+ FISH positive were regarded as positive. #According to Elston and Ellis
classification (see text for complete reference). *According to UICC-TNM
classification of malignant tumours, sixth edition 2002. °At initial diagnosis
time. n.s. = not significant; CR = complete response; PR = partial response;
SD = stable disease; PD = disease progression.
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received an association of docetaxel plus capecitabine).
Lastly, according to guidelines all HER2 positive patients
(both patients that achieve a response and patients who
did not) received trastuzumab while negative-ones were
treated with docetaxel (alone or in combination). The dif-
ference in treatment received and, notably, in the under-
lying cancer biology makes HER2 positive and negative
groups as different populations so affecting our data
interpretation.
Within that specific experimental context, IHC-assessed
nuclear p53 status failed to show any significant associa-
tion with outcome and survival parameters. In fact,
nuclear expression level of p53 did not differ between
responders and not-responders patients. Reasons for this
phenomenon cannot be limited to the above mentioned
study limitations, probably, should be seek in the mechan-
isms of action (MoA) of docetaxel and, to a lesser extent,
in technical limitations of p53 determination by IHC.
Docetaxel, a semi-synthetic analogue of paclitaxel, is a
promoter of microtubule stabilization by direct binding
leading to cell cycle arrest at G2/M and apoptosis
[33-35]. The b-subunit of the tubulin heterodimer, the
key component of cellular microtubules, represent the
molecular target of docetaxel [36]. This unique MoA
could offer a putative explanation for the lack of asso-
ciation between p53 status and docetaxel sensitivity. In
fact, docetaxel is not a direct DNA-damaging drug and
docetaxel-induced cell cycle arrest occurs in a late phase
of cell cycle (G2/M transition).
Conversely, p53 mainly (but not exclusively) acts in
early phases of cell cycle inducing, after DNA damage, a
G1 arrest by transactivation of p21Waf1/Cip1, a cyclin-
dependent kinase inhibitor [37-39]. Therefore, the sub-
cellular localization of docetaxel molecular target and
the timing of docetaxel action during cell cycle do not
overlap with those of p53 and this could explain, at least
in part, our negative results. Some opposite data were
published some years ago about a possible predictive
role of TP53 mutation on paclitaxel sensitivity in breast
cancer [22,23]; Johnson et al [23] proposed a model in
which the loss of p53 function reduced the G1 block
thus enhancing the efficacy of paclitaxel during mitosis.
Our data do not support this hypothesis even account-
ing for docetaxel over paclitaxel differences.
Lastly, the correlation between p53 nuclear storage
measured by IHC and p53 mutation detected by sequen-
cing has been estimated to be less than 75% in breast
carcinomas [40]. Indeed, not all mutations yield a stable
protein, and some mutations lead to an abnormal pro-
tein not detected by IHC. On the other hand, wild-type
p53 may accumulate in some tumors as a result of the
response to DNA damage, giving a positive IHC result
not accounting for TP53 mutation [41].
On the other hand, we observed a clear predictive
value for HER2 status. Patients with HER2-positive
tumors were more likely to respond to docetaxel treat-
ment even taking into account the small sample size.
This observation seems to be true independently of
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Figure 3 Kaplan-Meier curves for overall survival according to p53 or HER2 status. Kaplan-Meier curves for overall survival showed no-
significant separation between high vs low-espressors group for both p53 (left panel) and HER2 (right panel). Similar results were obtained for
disease-free survival (not shown).
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patient category (HER2-positive or negative); in fact, in
both the whole population and in HER2 subgroups it
seems that the higher is the FISH value the higher is
the probability to respond to docetaxel. In our opinion,
the most likely explanation of our data may resides in
the higher proliferation rate of this subset of cancers
[25]. Docetaxel, as near-all chemotherapeutic agents,
works better in tumors with an higher proliferation
index because cancer growth-rate it’s “per se” the main
determinant of cell sensitivity to non-target chemoter-
apy. Moreover, rapid growth cancers (as HER2 positive
breast cancer) have a greater percentage of cells in the
M phase of cell cycle and this could represent another
element to take into account.
More specific molecular mechanisms, i.e. as for topoi-
somerase II alpha, are unlikely. In fact, b-tubulin con-
sists of six isotypes, all of which have related aminoacid
sequences and are well conserved between species. Class
I-btubulin is the most commonly expressed isotype in
human beings, and the most common isotype in cancer
cells [42]. The class-I isotype is encoded by the TUBB
gene located at 6p2513 far from HER2 gene located on
chromosome 17. Thus a co-amplification phenomenon
is difficult to propose [42].
Conclusions
FISH-determined HER2 status may predict docetaxel
sensitivity in metastatic breast cancer and could be an
element to evaluate in the pre-treatment work-up.
Obviously, a further prospective validation on a larger
sample size is warranted before any possible clinical
application. Interestingly, HER2 is a well-known predic-
tor of trastuzumab efficacy and the association of trastu-
zumab plus taxanes can be considered as a standard of
care in the first-line setting, so the possibility to predict
treatment response by analysing one parameter (HER2)
could be an attractive option.
Conversely, p53 status lack of any significant associa-
tion with docetaxel sensitivity in the same setting. Prob-
ably, TP53 gene mutational analysis could be more
informative that IHC, even if a simplistic association
between TP53 gene status and taxane treatment
response seem to be unlikely given the wide and very
complicated molecular pathway related to p53.
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